

CURRICULUM VITAE

Date of Revision: October 1, 2023

Name: William Damsky, M.D., Ph.D.

Term:

Appointment: Assistant Professor of Dermatology and Pathology
Clinician-Scholar Track

School Yale University School of Medicine

Education:

B.S.	University of Vermont (Biology)	2000 - 2005
Ph.D.	University of Vermont College of Medicine Cell & Molecular Biology Advisor: Marcus Bosenberg MD, PhD	2007 - 2011
M.D.	University of Vermont College of Medicine	2005 - 2013

Postdoctoral Training

Clinical

Intern, Internal Medicine	Yale-New Haven Hospital	2013 - 2014
Resident, Dermatology	2+2 Research Track (T32 Fellow) Yale School of Medicine,	2014 - 2017
Chief Resident, Dermatology	Yale School of Medicine	2016 - 2017
Dermatopathology Fellow	Yale School of Medicine	2018 - 2020

Scientific

Research Fellow, Immunobiology	Yale School of Medicine Advisor: Susan Kaeck, PhD	2017 - 2018
Research Fellow, Immunobiology	Yale School of Medicine Advisor: Richard Flavell, PhD	2018 - 2023

Career/Academic Appointments:

2017 – 2019	Dermatologist	Cornell Scott Health Center
2017 – 2020	Instructor of Dermatology	Yale School of Medicine
2018 – present	Dermatologist	Yale Medicine
2018 – present	Dermatologist	VA Veteran's Hospital
2020 – present	Assistant Professor of Dermatology	Yale School of Medicine
2020 – present	Assistant Professor of Pathology	Yale School of Medicine
2020 – present	Dermatopathologist	Yale Medicine
2023 – present	Program in Translational Biomedicine	Yale School of Med

Administrative Positions:

2023 – present Clinical Competency Chair
Department of Dermatology, Yale School of Medicine

Dermatopathology Fellowship,

Board Certification:

Dermatology	American Board of Dermatology	2017
Dermatopathology	American Board of Dermatology	2020
	American Board of Pathology	2020

Professional Honors & Recognition

International/National/Regional

2022: Young Physician Scientist Award, American Society for Clinical Investigation
2021: Travel Grant Award Winner, Inflammatory Skin Disease Summit, New York, NY
2021: Robert E Leet and Clara Guthrie Patterson Trust Mentored Research Award
2020: Young Investigator Award, American Academy of Dermatology
2019: Travel Grant Award Winner, American Association of Sarcoidosis and Other Granulomatous disorders (AASOG)
2018: Todd Nagel Memorial Award, Skin Cancer Foundation
2018: Physician Scientist Career Development Award, Dermatology Foundation
2018: Travel Grant Award Winner, Inflammatory Skin Disease Summit, Vienna, Austria
2017: Dermatologist Investigator Research Fellowship, Dermatology Foundation
2010: Research Scholar Award, Joanna Nicolay Melanoma Research Foundation

University

2023: Early Achievement Award, University of Vermont College of Medicine Alumni Association
2012: Joseph B. Warshaw Award for Outstanding Dissertation, University of Vermont College of Medicine
2004: Lyman S. Rowell Award for Outstanding Thesis, University of Vermont
2003: URECA! Undergraduate Research Award Winner, University of Vermont
2002: HELiX Undergraduate Summer Research Award, University of Vermont
2002: HELiX Undergraduate Mini-Grant, University of Vermont
2001: CV Starr Scholarship, University of Vermont

Grant/Clinical Trials History:

Current Grants

Agency: Colton Center at Yale

Title: “Noninvasive skin protein assessment to guide targeted treatment selection in inflammatory skin diseases”

P.I.: William Damsky, MD, PhD

Percent effort: 2%

Total costs for project period: \$200,000

Project period: 06/01/2023-05/30/2025

Agency: Melanoma Research Alliance

Title: “Targeting Epigenetics to Enhance Anti-Melanoma Immunity”

Role: Co-Investigator

Percent effort: 2%

Direct costs per year: \$50,000
Total costs for project period: \$100,000
Project period: 6/1/2022 – 05/30/2024

Agency: NIAID

I.D.# K08 AI159229-01
Title: “Delineation of the immunobiology of sarcoidosis and characterization of the effects of Janus kinase inhibition”
Role: Principal investigator
Percent effort: 75%
Direct costs per year: \$172,260
Total costs for project period: \$861,300
Project period: 7/1/2021 – 6/30/2026

Current Clinical Trials

Agency: TWI Biotechnology
I.D.# NCT05580042
Title: An Open-Label, Single Arm, Phase I Study to Evaluate the Safety and Tolerability of AC-1101 Topical Gel in Patients with Granuloma Annulare”
Role: PI
Percent effort: 1%
Project period: 1/2023 – 6/2023

Agency: Incyte
I.D.# pending
Title: “Topical ruxolitinib in granuloma annulare: an opportunity for pathogenesis directed therapy”
Role: PI
Percent effort: 1%
Amount: \$200,000
Project period: 10/2023 – 12/2024

Agency: Pfizer
I.D.# NCT05696795
Title: “JAK1 inhibition in sarcoidosis: an opportunity for pathogenesis directed therapy”
Role: PI
Percent effort: 1%
Amount: \$150,000
Project period: 4/2023 – 10/2024

Agency: Pfizer
I.D.# NCT05650736
Title: “JAK1 inhibition in granuloma annulare: an opportunity for pathogenesis directed therapy”
Role: PI
Percent effort: 1%
Amount: \$125,000
Project period: 3/2023 – 9/2024

Agency: Bristol Meyers Squibb
I.D.# pending
Title: “TYK2 inhibition in sarcoidosis and granuloma annulare: an opportunity for pathogenesis directed therapy”
Role: PI
Percent effort: 1%
Amount: pending
Project period: pending

Pending Grants

Past Grants

Agency: Dermatology Foundation Dermatologist Investigator Research Fellowship
Title: “Modeling immune checkpoint inhibitor therapy in mice to optimize treatment strategies in melanoma”
P.I.: William Damsky M.D., Ph.D.
Percent effort: 75%
Total costs for project period: \$30,000
Project period: 07/01/2017 – 06/30/2018

Agency: Yale Skin Cancer SPORE: Career Enhancement Program (CEP) Award
Title: “Evaluating the role of cancer associated fibroblasts in modulating anti-melanoma immune responses”
P.I.: William Damsky M.D., Ph.D.
Percent effort: 0%
Total costs for project period: \$50,000
Project period: 07/01/2018 – 06/30/2019

Agency: Skin Cancer Foundation Research Grant
Title: “Elucidating and overcoming mechanisms of immunotherapy resistance in melanoma”
P.I.: William Damsky M.D., Ph.D.
Percent effort: 0%
Total costs for project period: \$50,000
Project period: 07/01/2018 – 12/31/2019

Agency: Dermatology Foundation (Career Development Award)
Title: “Elucidating and overcoming mechanisms of immunotherapy resistance in melanoma”
P.I.: William Damsky, M.D, Ph.D.
Role: PI
Percent effort: 75%
Direct costs per year: \$55,000
Total costs for project period: \$165,000
Project period: 07/01/2018 – 06/30/2021

Agency: Centers for Disease Control
Title: “Natural history study of rubella associated granulomatous lesions in aged individuals”
P.I.: Karolyn Wanat, M.D.
Role: Co-I

Effort: 0%
Direct costs per year: \$2175
Total costs for project period: \$2175
Project period: 8/30/2020 – 8/29/2021

Agency: Colton Center (Yale)

Title: “Cytokine RNA in situ hybridization to guide targeted treatment selection in dermatology”
Role: Principal investigator
Percent effort: 1%
Direct costs per year: \$88,392
Total costs for project period: \$88,392
Project period: 7/1/2020 – 12/30/2022

Agency: Robert E. Leet and Clara Guthrie Patterson Trust Mentored Research Award

Title: “Evaluating the role of Janus kinase inhibition in the treatment of sarcoidosis: focus on disease heterogeneity and T cell responses”
P.I.: William Damsky, M.D., Ph.D.
Role: PI
Percent effort: 2%
Direct costs per year: \$45,000
Total costs for project period: \$90,000
Project period: 07/01/2018 – 06/30/2021

Past Clinical Trials

Agency: Pfizer

I.D.# NCT03910543
Title: “Open-label trial of tofacitinib in cutaneous sarcoidosis and granuloma annulare”
Role: Principal Investigator
Percent effort: 1%
Total costs for project period: \$150,000
Project period: 12/01/2019 – 5/31/2021

Agency: Pfizer

I.D.# NCT04415151
Title: “Tofacitinib for treatment of moderate COVID-19 (I-TOMIC)”
PI: Hyung Chun, M.D., Ph.D.
Role: Sub-I
Percent effort: 0%
Project period: 6/2020 – 9/2022

Agency: Pfizer

Title: “IRAK4 inhibition for treatment of COVID-19 with ARDS (I-RAMIC)”
PI: Hyung Chun, M.D., Ph.D.
Role: Sub-I
Percent effort: 0%
Project period: 6/2020 – 9/2022

Invited Speaking Engagements, Presentations, Symposia & Workshops Not Affiliated With Yale:

International/National

- 2023 American Academy of Dermatology Annual Meeting, New Orleans, LA. “JAK inhibitors and granulomatous diseases update” in F118: Granulomatous Disorders of Adult Skin.
- 2023 American Academy of Dermatology Annual Meeting, New Orleans, LA. “Personalized medicine approaches to select the best treatment for patients with inflammatory skin diseases” in U041: Developing the next generation of targeted treatments for inflammatory skin diseases.
- 2023 American Academy of Dermatology Annual Meeting, New Orleans, LA. “JAK inhibitors for sarcoidosis and granuloma annulare: new treatments for old diseases” in S005: JAK inhibitors: a new frontier in dermatology.
- 2023 Skin of Color Society Annual Meeting, New Orleans, LA. “JAK inhibitors in the treatment of sarcoidosis”
- 2023 American Academy of Dermatology Innovation Academy, Tampa, FL. “New and emerging therapies for granulomatous skin diseases” in P024: New therapies for old diseases.
- 2023 South Beach Symposium, Miami, FL. “What happen’s when...” (A session on boxed warnings for JAK inhibitors in dermatology)
- 2023 South Beach Symposium, Miami, FL. “Bottom line: how to educate your patients” (A session on application of genomics to dermatology)
- 2023 Moving Forward With Sarcoidosis Conference, New York, NY. “JAK inhibitors in the treatment of cutaneous granulomatous disorders”
- 2022 Annual Medical Dermatology Meeting, British Association of Dermatologists, London, United Kingdom. “The immunology of granulomas”.
- 2022 Advanced Cell Diagnostics Symposium, Broad Institute, Boston, Massachusetts. “RNA based biomarker expression for personalization of therapy in inflammatory skin diseases”. **(Keynote)**
- 2022 Complex Medical Dermatology Virtual Course, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico. “Paradoxical inflammatory eruptions to molecularly targeted therapies in dermatology.”
- 2022 Global Dermatology Talks. “Sarcoidosis and granuloma annulare: molecular evaluation and new approaches to therapy”.
- 2022 JAK Inhibitors Drug Development Summit virtual meeting. Workshop leader “The JAK Class black box warning: the implications for the JAK inhibitor drug development landscape for dermatology and beyond”.
- 2022 JAK Inhibitors Drug Development Summit virtual meeting. “An exploration of the JAK Market & Identification of Indications with an Unmet Need”.
- 2022 Medical Dermatology Society annual meeting, Boston, MA. “JAK inhibitors in dermatology: what to know about these “new” kids on the block”.
- 2022 American Academy of Dermatology annual meeting, Boston, MA. “JAK inhibitors in sarcoidosis and granuloma annulare: new treatments for old diseases” in S032 – JAK inhibitors: a new frontier in dermatology.
- 2022 American Academy of Dermatology annual meeting, Boston, MA. “Granuloma Annulare: What’s new?” in F044 Granulomatous Disorders of the Adult Skin.
- 2021 American Society of Dermatopathology annual meeting. “Cutaneous manifestations of SARS-CoV-2 infection and vaccination: an update” in the Hermann Pinkus Basic Science course.
- 2021 European Society of Dermatology and Venerology annual meeting. “JAK inhibitors in sarcoidosis and granuloma annulare.” in Granulomatous Diseases session.
- 2021 JAK inhibitor drug development summit virtual meeting. “Past, Present & Future Combinatorial Opportunities with JAKis”. Invited panel discussion participant.

- 2021 JAK inhibitor drug development summit virtual meeting. “Exploring the role of JAK inhibition in the treatment of sarcoidosis and other granulomatous disorders”.
- 2021 Sarc-Fighter podcast. An invited one-hour interview on my research in sarcoidosis on this podcast.
- 2021 The Foundation for Sarcoidosis Research (FSR) Patient Summit, “Research updates in cutaneous sarcoidosis”, FSR virtual meeting.
- 2021 TouchIMMUNOLOGY, “The Brave AA1 study”.
- 2021 American Academy of Dermatology Annual Meeting, VMX Virtual meeting, “JAK inhibitors for sarcoidosis and granuloma annulare: new insights into old diseases” in JAK inhibitors a New Frontier in Dermatology.
- 2021 American Academy of Dermatology Annual Meeting, VMX Virtual meeting, “COVID vaccine reactions” in What’s New in Dermatopathology.
- 2020 Dialogues in Dermatology podcast, American Academy of Dermatology, “Janus Kinase Inhibition (in sarcoidosis and granuloma annulare)”. March 2020 (**Featured Free Episode**).
- 2020 American Academy of Dermatology Annual Meeting, VMX Virtual meeting “Sarcoidosis and Granuloma Annulare” in JAK inhibitors a New Frontier in Dermatology
- 2019 American Academy of Dermatology Annual Meeting, Washington, DC. “Sarcoidosis and Granuloma Annulare” in S051 – JAK inhibitors a New Frontier in Dermatology

Regional

- 2023 Human Translational Immunology Seminar, Yale School of Medicine, New Haven, CT. “Cutaneous granulomatous disorders: from bench to bedside and back again”
- 2023 Dermatology Grand Rounds, University of Washington Department of Dermatology, Seattle, WA. “Cutaneous granulomatous disorders: from bench to bedside and back again”
- 2023 Protein Biomarker Symposium, Olink, New Haven, CT. “Protein biomarkers in inflammatory skin disease”
- 2023 Advanced Cell Diagnostics Symposium, New Haven, CT. “RNA based biomarker expression for the personalization of therapy in inflammatory skin diseases”
- 2022 University of Pennsylvania, Philadelphia, Pennsylvania. “Personalized diagnosis and treatment selection in inflammatory skin disease: where do we stand”.
- 2022 Protein Biomarker Symposium, Olink, Boston, Massachusetts. “Molecular evaluation of the clinical response to a novel sarcoidosis therapy”. (**Keynote**)
- 2022 Yale Dermatology Grand Rounds. “What’s new in granuloma annulare”
- 2022 Yale Dermatology Grand Rounds. “Personalized diagnosis and treatment selection in inflammatory skin disease: where do we stand?”.
- 2021 Toronto Psoriasis Seminar & Robert S. Lester Postgraduate Dermatology Seminar. “Sarcoidosis and granuloma annulare: from bedside to benchtop and back”.
- 2021 New England Dermatologic Society annual meeting, New Haven, CT “Molecularly targeted therapy for sarcoidosis and granuloma annulare: from bedside to benchtop and back.”
- 2021 Immuno-Oncology Translational Network Steering Committee meeting. “Engineered cytokine immunotherapy in cancer”
- 2021 Yale Human Translational Immunology Series, Yale School of Medicine, New Haven, CT. Invited speaker. “Novel therapeutic approaches in sarcoidosis and other inflammatory disorders with macrophage activation”
- 2021 Massachusetts General Hospital, Harvard School of Medicine, Boston, MA. Invited Dermatology Grand Rounds lecture “Granulomatous disorders in dermatology: opportunities for understanding macrophage biology and developing novel therapeutic approaches”
- 2020 Tufts University School of Medicine, Boston, MA. Invited speaker by the MSTP for “Monday Night Dinner” physician-scientist career development event.

- 2020 University of Massachusetts Medical School, Worcester, MA. Invited speaker “Granulomatous disorders in dermatology: opportunities for understanding macrophage biology and developing novel therapeutic approaches”
- 2016 Connecticut Society of Dermatology and Dermatologic Surgery Meeting, Plantsville, Connecticut, “Immune checkpoint inhibitor induced bullous pemphigoid”

Peer-Reviewed Presentations & Symposia Given at Meetings Not Affiliated With Yale:

International/National

- 2021 Inflammatory Skin Disease Summit “Treatment of sarcoidosis with cutaneous involvement with tofacitinib: results of an open-label clinical trial with mechanistic insight”. New York, NY. Oral abstracts session.
- 2021 American Society of Dermatopathology Annual meeting. “RNA in situ hybridization permits evaluation of treatment relevant cytokines in routine skin biopsies of atopic dermatitis and psoriasis” in Oral abstract session.
- 2021 Society for Investigation Dermatology Annular Meeting (virtual), “Single-cell RNA sequencing (scRNA-seq) of sarcoidosis skin biopsies reveals key pathogenic cytokines and potential treatment targets” in Translational Concurrent Mini-Symposia.
- 2021 American Academy of Dermatology Annual Meeting, VMX Virtual meeting, “Treatment of sarcoidosis with cutaneous involvement with tofacitinib: results of an open-label clinical trial.” in Late-breaking session.
- 2019 American Society of Dermatopathology Annual Meeting, San Diego, California “STAT1 and STAT3 staining in necrobiosis lipoidica and immunohistopathologic findings during treatment with a JAK inhibitor”
- 2010 CD163 and Inflammation Conference, Sonderborg, Denmark “Altered recruitment and characteristics of tumor-infiltrating macrophages in a highly metastatic, endogeneous mouse model of melanoma”

Professional Service

Peer Review Groups/Grant Study Sections:

Journal Service:

Editor/Associate Editor

Editorial Board

2020 – 2022 Journal of the American Academy of Dermatology
Social Media Editor (Twitter)

Reviewer (Ad hoc)

2015 – present

Nature Communications, Science Immunology, Journal of Clinical Investigation, Journal of the American Academy of Dermatology (JAAD), JAAD Case Reports, Journal of Clinical Investigation, The Journal of Investigative Dermatology, Journal of the European Academy of Dermatology and Venerology (JEADV), JAMA Dermatology, British Journal of Dermatology, Pediatric Dermatology, Dermatologic Therapy, American Journal of Clinical Dermatology, International Journal of Dermatology, Therapeutic Advances in Musculoskeletal Diseases, Journal of Clinical Medicine, Arthritis Care and Research, British Medical Journal Case Reports, Yale Journal of Biology and

Medicine, British Journal of Cancer, BMC Medical Genomics, Tumor Biology, Clinical Medicine Insights: Oncology, Therapeutic Advances in Chronic Diseases, FASEB Journal, Journal of Dermatologic Treatment

Verified peer reviews (Publons): 95 reviews (98th percentile)

Professional Service for Professional Organizations:

2023	Grant reviewer (ad hoc), National Eczema Association
2023	International Society for Investigative Dermatology, Abstract Reviewer, ISDI annual meeting. Concurrent Mini-Symposium: Translational Studies
2022	Society for Investigator Dermatology annual meeting, Abstract Reviewer and session moderator. Concurrent Mini-Symposium #5: Translational Studies
2022	Chair, Day 2, JAK Inhibitor Innovation Summit virtual meeting.
2021 – present	Expert Faculty Board Member, touchIMMUNOLOGY
2019 – present	Virtual Slide Committee Member, American Society of Dermatopathology

Yale University Service:

University Committees

Medical School Committees

2021 – present	Member, Yale Center for Clinical Investigation (YCCI) User Advisory Committee
2020 – present	Member, Translational Medicine Working Group

Departmental Committees

2023-present	Member, Departmental Retreat Planning Committee
2021- present	Director, Resident Journal Club, Department of Dermatology
2017 - 2022	Member, Patient Safety and Quality Committee, Department of Derm
2020 - present	Member, Resident Selection Committee, Department of Dermatology
2020 – 2023	Twitter account editor, Department of Dermatology

Public Service:

2021	National Medical Association (NMA): Conducted mock dermatology residency interviews to support applications from groups traditionally underrepresented in medicine/dermatology
2021	Ad hoc grant reviewer, “LifeArc Philanthropic Fund”
2020 – present	Founder, “Global Dermatology Talks”
2018 – 2019	Clinical Education Seminar Leader (Dermatology), Cornell Scott Hill Health Center, New Haven, Connecticut
2012	Volunteer, Celiac Disease Support Group, Central Vermont Medical Center, Berlin, Vermont
2005 – 2009	Volunteer, Smile Docs, University of Vermont College of Medicine, Burlington, Vermont
2004	Volunteer, Vermont Respite House, Williston Vermont

Bibliography:

Citations = 6,399

h-index = 37

i-10 index = 54

Peer-Reviewed Original Research

1. Armbruster P, **Damsky, WE**, Giordano R, Birungi J, Munstermann LE, Conn JE (2009). Infection of new- and old-world *Aedes albopictus* (Diptera: culicidae) by the intracellular parasite *Wolbachia*: implications for host mitochondrial DNA evolution. *J Med Entomol.* 40:356-60.
2. **Damsky, WE**, Duncan, E., Flanagan, N., Fromhold, K., Dung, H., Meyer, R., Sax, J., Delaney, T., Bress, W., Hoffman-Contois, R., and Carney, J.K (2009). Public awareness of mercury in fish: analysis of public awareness and assessment of fish consumption in Vermont. *McGill J Med.* 12(2):39.
3. Dankort D, Curely DP, Cartlidge RA, Nelson B, Karnezis AN, **Damsky, WE**, You MJ, DePinho RA, McMahon M, and Bosenberg M (2009). Braf(V600E) cooperates
4. with Pten loss to induce metastatic melanoma. *Nature Genetics.* 41(5):544-52.
5. **Damsky, WE**, Curley, DP, Santhanakrishnan, M, Rosenbaum, LE, Platt, JT, Gould Rothberg, BE, Taketo, MM, Dankort, D, Rimm, DL, McMahon, M, and Bosenberg, M (2011). Beta-catenin levels control metastasis in Braf-activated Pten-deficient melanomas. *Cancer Cell.* 20(6):741-54. **(Issue cover article)**
6. **Damsky, WE**, Micevic, G, Meeth, K, Muthusamy, V, Curley, DP, Santhanakrishnan, M, Erdelyi, I, Platt, JT, Huang, L, Theodosakis, N, Zaidi, MR, Tighe, S, Davies, MA, Dankort, D, McMahon, M, Merlino, G, Bardeesy, N, and Bosenberg, M (2014). mTORC1 activation blocks BrafV600E-induced growth arrest, but is not sufficient for melanoma formation. *Cancer Cell.* 27(1):41–56. **(Issue Cover Article)**
7. Micevic, G, Muthusamy, V, **Damsky, W**, Theodosakis, N, Liu, X, Meeth, K, Wingrove, E, Santhanakrishnan, M, and Bosenberg, M (2016). DNMT3b modulates melanoma growth by controlling levels of mTORC2 component RICTOR. *Cell Reports.* 14(9):2180-92.
8. Ko, CJ, Antaya, RJ, Zubek, A, Craiglow, B, **Damsky, W**, Galan, A, and McNiff, JM (2016). Revisiting histopathologic findings in Goltz syndrome. *J Cutan Pathol* 43(5):418-21.
9. Meeth, K, Wang, J, Micevic, G, **Damsky, W**, and Bosenberg, M. (2016). The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations. *Pigment Cell Melanoma Res.* 29(5):590-7.
10. Wang, J, Perry, CJ, Meeth, K, Thakral, D, **Damsky, W**, et al. (2017). UV-induced somatic mutations elicit a functional T cell response in the YUMMER mouse melanoma model. *Pigment Cell Melanoma Res.* 30(4): 428-435.
11. Perry, C, Munoz-Rojas, A, Meeth, K, Kellman, L, Amezcua, R, Thakral, D, Du, V, Wang, J, **Damsky, W**, Kuhlmann, A, Sher, J, Bosenberg, M, Miller-Jensen, K, and Kaeck, S (2018). Myeloid-targeted immunotherapies act in synergy to induce inflammation and anti-tumor immunity. *J Exp Med.* 215:877-893.
12. Neubert NJ, Schmittnaegel M, Bordry N, Nassiri S, Wald N, Martignier C, Tile L, Homicsko K, **Damsky W**, Maby-El Hajjami H, Klamann I, Danenberg E, Ioannidou K, Kandalaft L, Cukos G, Hoves S, Ries CH, Fuertes Marraco SA, Foukas PG, De Palma M, and Speiser DE (2018). T cell-induced CSF1 promotes resistance to PD1 blockade. *Sci Transl Med.* 11(10): 1-14.
13. Wang Y, Nasiri AR, **Damsky WE**, Perry CJ, Zhang XM, Rabin-Court A, Pollak MN, Shulman GI, Perry RJ (2018). Uncoupling hepatic oxidative phosphorylation reduces tumor growth in two murine models of colon cancer. *Cell Reports.* 24(1): 47-55.
14. Siegel J, Totonchy M, **Damsky W**, Berk-Krauss J, Castiglione F Jr, Sznol M, Petrylak DP, Fischbach N, Goldberg SB, Decker RH, Stamatouli AM, Hafez N, Glusac EJ, Tomaykop MM,

- and Leventhal JS (2018). Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. *J Am Acad Dermatol*. 79(6):1081-1088.
15. Dura B, Choi JY, Zhang K, **Damsky W**, Thakral D, Bosenberg M, Craft J, Fan R (2018). scFTD-seq: free-thaw lysis based, portable approach toward a highly distributed single-cell 3' mRNA profiling. *Nucleic Acids Res*. 47:e16.
 16. **Damsky W**, Thakral D, Emeagwali N, Galan A, King B (2018). Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis. *N Engl J Med*. 379(26):2540-2546.
 17. **Damsky W**, Jilaveanu L, Turner N, Perry C, Zito C, Tomayko M, Leventhal J, Herold K, Meffre E, Bosenberg M, Kluger HM. B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitor. *J Immunother Cancer*. 7(1): 153.
 18. Lemes BM, Assis de Andrade E, Cruz LS, Minozzo BR, Carey WD, **Damsky W**, et al. (2019). Effect of injection solutions in the dispersion of syringe lubricant (silicone oil). *J. Am. Acad. Dermatol*. 82(3):747-749.
 19. Etzerodt A, Tsalkitzi K, Maniecki M, **Damsky W**, et al. (2019). Specific targeting of CD163+ TAMs mobilizes inflammatory monocytes and promotes T cell-mediated tumor regression. *J Exp Med*. 216(100):2394-2411.
 20. **Damsky W**, Vesely MD, Lee AI, Choi J, Meyer AC, Chen M, Ahmad T, King B (2019). Drug-induced hypersensitivity syndrome with myocardial involvement treated with tofacitinib. *JAAD Case Rep*. 5(12):1018-1026.
 21. **Damsky W**, Thakral D, McGeary MK, Leventhal J, Galan A, King B (2020). Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare. *J Am Acad Dermatol*. 82(3):612-261.
 22. **Damsky W**, Young BD, Sloan B, Miller EJ, Obando JA, King B (2020). Treatment of multiorgan sarcoidosis with tofacitinib. *ACR Open Rheumatol*. 2(2):106-109.
 23. **Damsky W**, Wang A, Olamiju B, Peterson D, Galan A, King B. (2020). Treatment of severe lichen planus with the JAK inhibitor tofacitinib. *J Allergy Clin Immunol*. 145(6):1708-1710.
 24. **Damsky W**, Patel D, Garelli CJ, Garg M, Wang A, Dresser K, Deng A, Harris JE, Richmond J, King B. (2020). JAK inhibition prevents bleomycin-induced fibrosis in mice and is effective in morphea. *J Invest Dermatol*. 140(7):1446-1449.
 25. Hornick N, Wang A, Lim Y, Gehlhausen J, Siegel J, Wang J, Foss F, Lim I, Zubek A, Milstone L, Galan A, King B, **Damsky W**. (2020). Development or worsening of sarcoidosis with IL-17 blockade for psoriasis. *J Eur Acad Dermatol Venerol*. 34(10):e583-e585.
 26. Wang A, Hornick, N, Lim Y, Gehlhausen J, Siegel J, Wang J, Foss F, Lim I, Zubek A, Milstone L, Galan A, King B, **Damsky W**. (2020). Interleukin-17 blockade downregulates NOD2 in skin and may promote paradoxical psoriasis. *J Eur Acad Dermatol Venerol*. 34(9): e497-e499.
 27. Ligtenberg KG, Hu JK, **Damsky W**, Olno K, Kluger H, Clune J, Cowper SE, Panse G, Leventhal J, Weiss S. (2020). Neoadjuvant anti-programmed cell death 1 therapy for locally advanced basal cell carcinoma in treatment-naïve patients: a case series. *JAAD Case Rep*. 6(7):628-633.
 28. Zhou T*, **Damsky W***, Weizman OE*, McGeary MK, Hartmann KP, Rosen CE, Fischer S, Jackson R, Flavell RA, Wang J, Sanmamed MF, Bosenberg MW, Ring AM (2020). IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy. *Nature*. 583(7817):609-614. *Contributed equally.
 29. Wang A, Rahman NT, McGeary MK, Murphy M, McHenry A, Peterson D, Bosenberg M, Flavell RA, King B, **Damsky W** (2020). Treatment of granuloma annulare and suppression of proinflammatory cytokine activity with tofacitinib. *J. Allergy Clin. Immunol*. 147(5): 1795-1809.
 30. Meizlish ML, Pine AB, Bishai JD, Goshua G, Nadelmann ER, Simonov M, Chang CH, Zhang H, Shallow M, Bahel P, Owusu K, Yamamoto Y, Arora T, Atri DS, Patel A, Gbyli R, Kwan J,

- Won CH, Dela Cruz C, Price C, Koff J, King BA, Rinder HM, Wilson FP, Hwa J, Halene S, **Damsky W**, van Dijk D, Lee AI, Chun H. (2020). A neutrophil activation signature predicts critical illness and mortality in COVID-19. **Blood Adv.** 5(5): 1164-1177.
31. Ko CJ, Harigopal M, Gehlhausen JR, Bosenberg M, McNiff JM, **Damsky W**. (2020). Discordant anti-SARS-CoV-2 spike protein and RNA staining in cutaneous pernioic lesions suggests endothelial deposition of cleaved spike protein. **J. Cutan. Pathol.** 48(1):47-52.
 32. Ko CJ, Harigopal M, **Damsky W**, Gehlhausen JR, Bosenberg M, Patrignelli R, McNiff JM. (2020). Perniosis during the COVID-19 pandemic: negative anti-SARS-CoV-2 immunohistochemistry in six patients and comparison of pernioic lesions before the emergence of SARS-CoV-2. **J. Cutan. Pathol.** 47(11): 997-1002.
 33. Ko CJ, Wang A, Panse G, Lee EE, Wang RC, Whang PG, Bosenberg M, **Damsky W** (2021). HpyV6- and HpyV7-negative parakeratosis and dyskeratosis in squamous cell carcinoma in situ. **J. Cutan. Pathol.** 48(7): 998-1000.
 34. Tomayko, MM*, Damsky W*, Fathy R, McMahon DE, Turner N, Valentin MN, Rallis T, Aivaz O, Fox LP, Freeman EE (2021). Subepidermal blistering eruptions including bullous pemphigoid following COVID-19 vaccination. **J All Clin Immunol.** 148(3): 750-751. *Contributed equally.
 35. Zhang SM, Cai WL, Liu X, Thakral D, Luo J, Chan LH, McGeary MK, Song E, Blenman KRM, Micevic G, Jessel S, Zhang Y, Yin M, Booth CJ, Jilaveanu LB, **Damsky W**, Sznol M, Kluger HM, Iwasaki A, Bosenberg MW, Yan Q (2021). **Nature.** 598(7882): 682-687.
 36. Wang SY, Takahashi T, Pine AB, **Damsky WE**, Simonov M, Zhang Y, Kieras E, Price CC, King BA, Siegel MD, Desir GV, Lee AI, Iwasaki A, Chun HJ (2021). Challenges in interpreting cytokine data in COVID-19 affect patient care and management. **PLoS Biol.** 19(8):e3001373.
 37. Leasure AC, **Damsky W**, Cohen JM (2021). Comorbidities associated with granuloma annulare: a case-control study in the All of Us research program. **J. Am. Acad. Dermatol.** 87(1):197-199.
 38. McMahon DE, Kovarik CL, **Damsky W**, Rosenbach M, Lipoff JB, Tyagi A, Chamberlin G, Fathy R, Nazarian RM, Desai SR, Lim HW, Thiers BH, Hruza GJ, French LE, Blumenthal K, Fox LP, Freeman EE. (2021). Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: a registry based study. **J. Am. Acad. Dermatol.** S0190-9622(21)02442-7.
 39. Leasure AC, **Damsky W**, Cohen JM (2020). Prevalence of granuloma annulare in the United States: a cross-sectional study in the All of Us Research Program. **Int. J. Dermatol.** 61: e301-e302.
 40. Murphy MJ, Gruenstein D, Wang A, Peterson D, Levitt J, King B, **Damsky W** (2021). Treatment of persistent erythema multiforme with Janus kinase inhibition and the role of interferon gamma and interleukin 15 in its pathogenesis. **JAMA Dermatol.** 157(12):1477-1482.
 41. Weiss SA, Djureinovic D, Jessel S, Krykbaeva I, Zhang L, Jilaveanu L, Ralabate A, Johnson B, Levit NS, Anderson G, Zelterman D, Wei W, Majan A, Trifan O, Bosenberg M, Kaech SM, Perry CJ, **Damsky W**, Gettinger S, Sznol M, Hurtwitz M, Kluger HM (2021). A phase I study of APX005M and cabiralizumab with or without nivolumab in patients with melanoma, kidney cancer, or non-small cell lung cancer resistant to anti-PD-1/PD-L1. **Clin Cancer Res.** 27(17):4757-4767.
 42. Wang A, Fogel AL, Murphy MJ, Panse G, McGeary MK, McNiff JM, Bosenberg M, Vesely MD, Cohen JM, Ko CJ, King BA, **Damsky W** (2021). Cytokine RNA in situ hybridization permits individualized molecular phenotyping in biopsies of psoriasis and atopic dermatitis. **JID Innov.** 1(2):100021.
 43. Gehlhausen JR, Little AJ, Ko CJ, Emmenegger M, Lucas C, Wong P, Klein J, Lu P, Mao T, Jaycox J, Wang E; Yale IMPACT Team, Ugwu N, Muenker C, Mekael D, Klein RQ, Patrignelli R, Antaya R, McNiff J, **Damsky W**, Kamath K, Shon J, Ring AM, Yildirim I, Omer S, Ko AI,

- Aguzzi A, Iwasaki A (2022). Lack of association between pandemic chilblains and SARS-CoV-2 infection. *Proc. Natl. Acad. Sci. U S A* 119(9):e2122090119.
44. **Damsky W**, Wang A, Kim DJ, Young BD, Singh K, Murphy MJ, Daccache J, Clark A, Ayasun R, Ryu C, McGearry MK, Odell ID, Fazzone-Chettiar R, Pucar D, Homer R, Gulati M, Miller EJ, Bosenberg M, Flavell RA, King B (2022). Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis. *Nat. Commun.* 13(1):3140.
45. Fan R, Leasure AC, **Damsky W**, Cohen J (2022). Association between atopic dermatitis and COVID-19 infection: a case control study in the All of Us research program. *JAAD Int.* 6:77-81.
46. Fan R, Leasure AC, **Damsky W**, Cohen JM (2022). Association of atopic dermatitis with attention-deficit hyperactivity disorder among US adults in the “All of Us” research program: a case control study. *J. Am. Acad. Dermatol.* 87: 691-692.
47. Ricardo-Gonzalez RR, Kotas ME, O’Leary CE, Singh K, **Damsky W**, Liao C, Arouge E, Tenvooren I, Marquez DM, Schroeder AW, Cohen JN, Fasset MS, Lee J, Daniel SG, Bittinger K, Diaz RE, Fraser JS, Ali N, Ansel KM, Spitzer MH, Liang HE, Locksley RM (2022). Innate type 2 immunity controls hair follicle commensalism by Demodex mites. *Immunity.* 55(10):1891-1908.
48. Ederaine SA, Kimball KM, Enwereji N, Ftouni R, Daneshjou R, Junejo MH, **Damsky W***, Richmond JM* (2022). Global dermatology talks is a virtual lecture series for equitable dissemination of dermatologic information. *JAAD Int.* 9:116-118. (*Co-senior author)
49. Ren J, Qu R, Rahman NT, Lewis JM, King ALO, Liao X, Mirza FN, Carlson HR, Huang Y, Gigante S, Evans B, Rajendran BK, Xu S, Wang G, Foss FM, **Damsky W**, Kluger Y, Krishnaswamy S, Girardi M (2022). Integrative transcriptome and trajectory analysis of cutaneous T cell lymphoma identified putative precancer populations. *Blood Adv.* 7: 445-457.
50. Hodelin C, Fan R, **Damsky W**, Cohen JM (2022). The association of atopic dermatitis and chronic rhinosinusitis in adults: a cross-sectional study using the All of Us research program. *Int J Dermatol.* 62: e430-e431.
51. Fan R, Leasure AC, **Damsky W**, Cohen JM (2022). Alcohol use disorder among adults with atopic dermatitis: a case-control study in the All of Us research program. *J Am Acad Dermatol.* 87: 1378-1380.
52. Fan R, Leasure AC, **Damsky W**, Cohen JM (2022). Association between atopic dermatitis and COVID-19 infection: a case-control study in the All of Us research program. *JAAD Int.* 6:77-81.
53. Murphy MJ, Cheraghlou S, **Damsky W**, Cohen JM (2022). Utilization, cost, and prescription patterns of dupilumab among Medicare beneficiaries in the United States from 2017 to 2019. *J Dermatolog Treat.* 33:3214-3215.
54. Choi R, Wang JX, **Damsky W**, Galan A, Leventhal J (2022). Janus kinase-signal transducers and activators of transcription (JAK-STAT) activation in anti-programmed death-1 (PD-1) therapy associated granuloma annulare. *Int J Dermatol.* 62: e323-e325.
55. Fan R, Leasure AC, **Damsky W**, Cohen JM (2023). Migraine among adults with atopic dermatitis: a cross-sectional study in the All of Us research programme. *Clin Exp Dermatol* 48:24-26.
56. Berna R, Margolis DJ, **Damsky W**, Barbieri JS (2023). Annual health care utilization and cost of granuloma annulare in the United States, 2016 to 2019: a cross-sectional study. *J. Am. Acad. Dermatol.* 88:217-219.
57. Clark A, Murphy MJ, King B, Cohen JM, Rosenbach M, Barbieri J, Damsky W (2023). Patient perspective on the lived experience of granuloma annulare *Br J Dermatol.* 188:134-136.
58. Singh K, Valido K, Swallow M, Okifo KO, Wang A, Cohen JM, **Damsky W** (2023). Baseline cytokine profiles determined by RNA in situ hybridization correlate with response to dupilumab in patients with eczematous dermatitis. *J Am Acad Dermatol.* *J Am Acad Dermatol.* 88:1094-1100.

59. Chen JS, Murphy MJ, Singh K, Wang A, Chow RD, King SR, Cohen JM, Ko C, **Damsky W**. (2023). IL17A mRNA staining distinguished palmoplantar psoriasis from hyperkeratotic palmoplantar eczema in diagnostic skin biopsies. *JID Innov.* 3: 100189.
60. Damo M, Hornick NI, Venkat, A, William I, Clulo K, Venkatesan S, He J, Loza JL, Kwok D, Tal A, Buck J, Cui C, Singh J, **Damsky W**, Leventhal JS, Krishnaswamy S, Joshi NS (2023). PD-1 maintains CD8 T cell tolerance towards cutaneous neoantigens. *Nature*. 619:151-159.
61. Murphy MJ, Heyang M, Fan R, Leasure AC, **Damsky W**, Cohen JM (2023). Association between uveitis and lichen planus in the all of us research program. *Arch Dermatol Res.* 315: 2729-2730.
62. Fan R, Chen G, Leasure AC, Johnson MC, **Damsky W**, Cohen JM (2023). Association of atopic dermatitis with schizophrenia and schizoaffective disorder. *Arch Dermatol Res.* 315: 2731-2733.
63. Krykbaeva I, Bridges K, **Damsky W**, Pizzurro GA, Alexander AF, McGear MK, Park K, Muthusamy V, Eyles J, Luheshi N, Turner N, Weiss SA, Olino K, Kaech SM, Kluger HM, Miller-Jense K, Bosenberg M (2023). Combinatorial immunotherapy with agonistic CD40 activates dendritic cells to express IL12 and overcome PD-1 resistance. *Cancer Immunol Res.* [Online ahead of print].
64. Shipman WD, Singh K, Cohen JM, Leventhal J, **Damsky W**, Tomayko MM (2023). Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment. *Br J Dermatol.* 189: 339-341.
65. Horowitch B, Lee, DY, Ding M, Martinez-Morilla S, Aung TN, Ouerghi F, Wang X, Wei W, **Damsky W**, Sznol M, Kluger H, Rimm DL, Ishizuka JJ (2023). Subsets of IFN signaling predict response to immune checkpoint blockade in patients with melanoma. *Clin Cancer Res.* 29: 2908-2918.
66. Belzer, A, Leasure AC, **Damsky W**, Cohen JM (2023). The association of anxiety with granuloma annulare: a case-control study of the National Institutes of Health ‘All of Us’ research programme. *Br J Dermatol.* 188: 558-560.
67. Joel MZ, Fan R, **Damsky W**, Cohen JM (2023). Psoriasis associated with asthma and allergic rhinitis: a US-based cross-sectional study using the All of Us Research Program. *Arch Dermatol Res.* 315: 1823-1826.
68. Singh K, Valido K, Swallow M, Okifo KO, Wang A, Cohen JM, **Damsky W** (2023). Baseline skin cytokine profiles determined by RNA in situ hybridization correlate with response to dupilumab in patients with eczematous dermatitis. *J Am Acad Dermatol.* 88: 1094-1100.
69. Singh I, Leitner BP, Wang Y, Zhang H, Joseph P, Lutchmansingh DD, Gulati M, Possick JD, **Damsky W**, Hwa J, Heerdt PM, Chun HJ (2023). Proteomic profiling demonstrates inflammatory and endotheliopathy signatures associated with impaired cardiopulmonary exercise hemodynamic profile in post acute sequelae of SARS-CoV-2 infection (PASC) syndrome. *Pulm Circ.* 13: e122220.

Chapters, Books, and Reviews

70. **Damsky WE** and Bosenberg, M (2010). Mouse melanoma models and cell lines. *Pigment Cell Melanoma Res.* 23:853-59.
71. **Damsky, WE**, Rosenbaum, LE, and Bosenberg, M (2011). Decoding melanoma metastasis. *Cancers.* 3:126-63.
72. **Damsky, WE**, Theodosakis, N, and Bosenberg, M (2013). Melanoma metastasis: new concepts and evolving paradigms. *Oncogene.* 33(19): 2413-22.
73. **Damsky, W** and Choi, J (2016). Genetics of cutaneous T cell lymphoma: from bench to bedside. *Current Treat Options Oncol.* 17(7):33.
74. **Damsky, W** and King, BA (2017). JAK inhibitor use in dermatology: the promise of a new drug class. *J. Am. Acad. Dermatol.* 76(4):736-744. (One of the most highly cited JAAD articles).

75. **Damsky, W** and Bosenberg, M (2017). Melanocytic nevi and melanoma: unraveling a complex relationship. *Oncogene*. 36(42): 5771-5792.
76. **Contributor to:** Leventhal J. and Levy L. Self-Assessment in Dermatology. 2019. Elsevier.
77. Wang A, Singh K, Ibrahim W, King B, **Damsky W**. (2020). The promise of JAK inhibitors for treatment of sarcoidosis and other inflammatory disorders with macrophage activation. *Yale J Biol Med*. 93(1):187-195.
78. Murphy MJ, Cohen JM, Vesely MD, **Damsky W**. (2020). Paradoxical eruptions to targeted therapies in dermatology: a systematic review and analysis. *J. Am. Acad. Dermatol*. 86(5): 1080-1091.
79. **Damsky W**, Peterson D, Ramseier J, Al-Bawardy B, Chun H, Proctor D, Strand V, Flavell RA, King B. (2020). The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases. *J. Allergy Clin. Immunol*. 147(3): 814-826.
80. **Damsky W**, Glusac EJ, Ko CJ (2023): Chapter 14 Noninfectious granulomas. Lever's Dermatopathology (12th Edition). Wolters Kluwer.
81. Murphy M and **Damsky W** (2023): Chapter 16 Sarcoidosis. Fitzpatrick's Therapeutics: A Clinician's Guide to Dermatologic Treatment. McGraw Hill.
82. Mortlock RD, Ma EC, Cohen JM, **Damsky W** (2023). Assessment of treatment-relevant immune biomarkers in psoriasis and atopic dermatitis: toward personalized medicine in dermatology. *J Invest Dermatol*. 143: 1412-1422.
83. Wei, BM, Fox LP, Kaffenberger BH, Korman AM, Micheletti RG, Mostaghimi A, Noe MH, Rosenbach M, Shinkai K, Kawh JH, Phillips EJ, Bologna JL, **Damsky W**, Nelson CA (2023). Drug-induced hypersensitivity syndrome / drug reaction with eosinophilia and systemic symptoms: Part I. Epidemiology, pathogenesis, clinicopathological features, and prognosis. *J Am Acad Dermatol*. [Online ahead of print].
84. Wei, BM, Fox LP, Kaffenberger BH, Korman AM, Micheletti RG, Mostaghimi A, Noe MH, Rosenbach M, Shinkai K, Kawh JH, Phillips EJ, Bologna JL, **Damsky W**, Nelson CA (2023). Drug-induced hypersensitivity syndrome / drug reaction with eosinophilia and systemic symptoms: Part II. Diagnosis and Management. *J Am Acad Dermatol*. [Online ahead of print].
85. Hwang E, Abdelghaffar M, Shields BE, **Damsky W** (2023). Molecularly targeted therapies for inflammatory cutaneous granulomatous disorders: a review of the evidence and implications for understanding disease pathogenesis. *JID Innov*. 3: 100220.
86. Nihal A, Caplan AS, Rosenbach M, **Damsky W**, Mangold AR, Shields BE (2023). Treatment options for necrobiosis lipoidica: a systematic review. *Int J Dermatol*. [Online ahead of print].

Peer-Reviewed Educational Materials

Invited Editorials and Commentaries

87. **Damsky WE** and Bosenberg, M (2011). Unwelcome guests: macrophages promote UV-induced melanoma. *Pigment Cell Melanoma Res*. 24:265-67.
88. **Damsky, WE** and Bosenberg, MW (2012). From bedding to bedside: genetically engineered mouse models of cancer inform concurrent clinical trials. *Pigment Cell Melanoma Res*. 25(4):404-5.
89. **Damsky W** and King B (2019). Targeted treatment of TREX1 chilblain lupus and other interferonopathies- taming T rex. *JAMA Dermatol*. 155(3):283-284.
90. Peterson D, **Damsky W**, King B. (2020). Reply: Calm before the storm: understanding the role of Janus kinase inhibitors in COVID-19. *J. Am. Acad. Dermatol*. 83(1):e67-e68.
91. **Damsky W** and King B. (2020). Calming the cytokine storm: the potential role of JAK inhibitors in treating COVID-19. *The Dermatologist*. 28(5).

92. **Damsky W**, Peterson D, King B. (2020). When interferon tiptoes through COVID-19: pernio-like lesions and their prognostic implications during SARS-CoV-2 infection. *J. Am. Acad. Dermatol.* 83(3):e269-e270.

Practice Guidelines, Standards and Consensus Statements

Case Reports, Technical Notes, Letters

78. **Damsky, WE**, Craiglow, BG, and Choi, J (2016). A discordant eruption in a neonatal twin. *JAMA Dermatol.* 152(4):463-4.
79. **Damsky, WE**, Leventhal, JS, Khalil, D, Vesely, MD, Craiglow, BG, Milstone, LM, and Choate, KA (2016). Recurrent coxsackievirus infection in a patient with lamellar ichthyosis. *Pediatric Dermatol.* 33:e140-2.
80. **Damsky, W** and King, BA (2016). STATing the obvious: it's time for new treatments in atopic dermatitis. *Br. J. Dermatol.* 175(5): 861-862.
81. **Damsky, W**, Kole, L, and Tomayko, MM (2016). Development of bullous pemphigoid during nivolumab therapy. *JAAD Case Rep.* 2(6): 442-444.
82. **Damsky W** and King, BA (2016). Idiopathic erythema multiforme: evidence of underlying janus kinase-signal transducer and activator of transcription activation and successful treatment with tofacitinib. *JAAD Case Rep.* 2(6): 502-504.
83. **Damsky, W***, Li, Alvin* and King BA (2017). Keratosis lichenoides chronica successfully treated with isotretinoin and methotrexate. *JAAD Case Rep.* (3)3: 205-207. *Co-first authors.
84. Kim SR, Charos A, **Damsky W**, Heald P, Girardi M, and King BA (2018). Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib. *JAAD Case Rep.* 4(5): 443-445.
85. **Damsky, W** and King, BA. (2020). Treatment of granuloma annulare with tofacitinib 2% ointment. *JAAD Case Rep.* 6(1):69-71.
86. Peterson D, **Damsky**, King, B. (2020). The use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). *J Am Acad Dermatol.* 82(6):e223-e226.
87. **Damsky W**, Singh K, Galan A, King B. (2020). Treatment of necrobiosis lipoidica with combination Janus kinase inhibition and intralesional corticosteroid. *JAAD Case Rep.* 6(2):133-135.
88. Gehlhausen JR, Ko CJ, **Damsky W**. (2020). Response to Tembhre et al.: 'Enhanced expression of ACE2 in psoriatic skin and its upregulation in keratinocytes by interferon-gamma: implications of inflammatory milieu in skin tropism of SARS-CoV-2. *Br. J. Dermatol.* 184(5): 984.
89. Won C, **Damsky W**, Singh I, Joseph P, Chichra A, Oakland H, Lu J, Vallabhajosyula P, Bardia A, Szabo C, Wang A, Borges K, Koff J, Rochester C, King B, Chun H (2020). Hijacking the SARS-CoV-2 cytokinopathy: Janus kinase inhibitors for moderate to severe COVID-19. SSRN preprint ID 3606658. Posted 9 Jun 2020.
90. Singh K, Wang A, Heald P, McNiff JM, Suozzi K, King B, Leventhal J, Damsky W. (2020). Treatment of angiolupoid sarcoidosis with tofacitinib 2% ointment and pulsed dye laser therapy. *JAAD Case Rep.* 7:122-124.
91. Zhou A, **Damsky W**, Girardi M, Foss FM, Vesely MD (2021). Necrotic papulonodules on the legs. *JAAD Case Rep.* 11:10-12.
92. Pach J, Olamiju B, Weiss S, **Damsky W**, Leventhal J (2021). Subcutaneous fat necrosis during nivolumab therapy for metastatic melanoma. *JAMA Dermatol.* 157(4): 468-469.
93. Murphy MJ, **Damsky W**, Vesely MD (2021). A pruritic psoriatic plaque develops at the donor site of an autologous skin graft: Koebner phenomenon. *Lancet* 398(10313):1836.

94. Cohen JM and **Damsky W** (2021). Comment on: Development of psoriasis during treatment with dupilumab: a systematic review. *J Am Acad Dermatol*. 86(3):e115.
95. Mirza FN, Wang A, Ramachandran SM, **Damsky W**, Cohen JM (2021). Dupilumab-induced phenotype switch from atopic dermatitis to psoriasis is characterized by de novo interleukin-17A expression: a case report. *Br. J. Dermatol*. 185(2): 432-434.
96. Talty R, Damsky W, King B (2021). Treatment of cutaneous sarcoidosis with tofacitinib: a case report and review of evidence of Janus kinase inhibition in sarcoidosis. *JAAD Case Rep*. 16:62-64.
97. Xie CB, Ring N, Damsky W, McNiff JM, Olino K, Odell I (2021). Squamous cell carcinoma arising in long-standing necrobiosis lipoidica treated with radical resection and split-thickness skin graft. *JAAD Case Rep*. 19:90-93.
98. Peterson, DM, **Damsky W**, Vesely MD (2022). Fever, Hypotension, and a Worsening Necrotic Wound. *JAMA* 327(15):1496-1497.
99. Peterson DM, **Damsky W**, Vesely MD (2022). Treatment of lichen sclerosus and hypertrophic scars with dupilumab. *JAAD Case Rep*. 23:76-78.
100. Briggs N, Wei BM, Ahuja C, Baker C, Foppiano PC, Lee E, O'Grady N, Singanamala S, Singh K, Bandaranayake TD, Cohen JM, **Damsky W**, Davis MW, Mejia R, Nelson CA, Topal JE, Azar MM (2022). Mucocutaneous Leishmaniasis in a pregnant immigrant. *Open Forum Infect Dis*. 9:ofac360.
101. Talty R, Micevic G, Damsky W, King BA (2022). Erythrodermic scabies in an immunocompetent patient. *JAAD Case Rep*. 29:112-115.
102. Fan R, Johnston MS, Gowen MF, **Damsky W**, Odell I, Clune J, Vesely MD (2022). Amelanotic melanoma in a patient with Hermansky-Pudlak syndrome. *JAAD Case Rep*. 27:61-63.
103. Talty R, **Damsky W**, King B (2022). Sisaihp alopecia treated with tofacitinib and oral minodixil. *JAAD Case Rep*. 29:41-42.
104. Talty R, Micevic G, Wang A, Ko CJ, **Damsky W** (2022). Leukoderma Induced by Rotigotine Patch, a Transdermal Dopamine Agonist. *Case Rep Dermatol*. 14:214-218.
105. Ahmad M, Murphy MJ, **Damsky W**, Leventhal J (2022). Dupilumab-induced psoriasis in the setting of pembrolizumab therapy: an analysis of cytokine expression. *Int J Dermatol*. 62: e424-e426.
106. Cohen JM, Damsky W, Giorardi M (2022). Comment on "Diagnostic testing of eczematous dermatitis with incomplete response to dupilumab" *J Am Acad Dermatol*. 87:e241-e242.
107. Murphy MJ, Leasure AC, **Damsky W**, Cohen JM (2023). Association of sarcoidosis with psoriasis: a cross-sectional study in the All of Us research program. *Arch Dermatol Res*. 315: 1439-1441.
108. Xu S, Singh K, McNiff J, **Damsky W**, Gehlhausen JR (2022). A case of eosinophilic dermatosis of hematologic malignancy with tissue-based Th2 cytokine profiling. *JAAD Case Rep*. 30:5-7.
109. Choi R, Garritano J, Laird M, Johnston M, Tkachenko E, **Damsky W**, Little AJ, McNiff J, Girardi M, Nelson CA (2022). Treatment of toxic epidermonecrosis and concurrent COVID-19-associated hyperinflammatory syndrome with systemic corticosteroids and etanercept. *JAAD Case Rep*. 29: 139.141.
110. Belzer A, Weiss E, Etaee F, Bunick C, **Damsky W**, Nelson CA (2022). *Stenotrophomonas maltophilia*, a pathogen of increasing relevance to dermatologists: a case report and review of the literature. *Antibiotics (Basel)*. 11:1398.
111. Park JJ, Park E, **Damsky W**, Vesely MD (2023). Pembrolizumab-induced lichenoid dermatitis treated with dupilumab. *JAAD Case Rep*. 37:13-15.
112. Xu S, Weiss E, Singh K, **Damsky W**, Girardi M (2023). A case of bullous lesions in cutaneous T-cell lymphoma. *JAAD Case Rep*. 35: 90-93.

113. Roy SF, Sarhan J, Liu X, Murphy MJ, Bunick CG, Choate KA, **Damsky W**, McNiff JM (2023). Inguinal patch in mpox (monkeypox) virus infection and eccrine syringometaplasia: report of two cases with in situ hybridization and electron microscopy findings. *Br J Dermatol*. 188:574-576.